BingfeiY Profile Banner
Bingfei Yu Profile
Bingfei Yu

@BingfeiY

Followers
841
Following
612
Statuses
371

Assistant Professor @USC |Parker Bridge Fellow | Postdoc @Stanford | PhD @UCSD | Immunogenomics + immunoengineering

Redwood City, CA
Joined April 2018
Don't wanna be here? Send us removal request.
@BingfeiY
Bingfei Yu
2 years
Our work on ENTER is finally out @CellCellPress! Like📱that can 📷📞🎧, ENTER is a modular viral platform that unifies multiple applications: ⭐️Decode Ligand-Receptor interaction ⭐️Receptor-specific cargo delivery ⭐️Link receptor specificity with cell state at single cell
Tweet media one
10
102
471
@BingfeiY
Bingfei Yu
5 days
RT @darbysaxbe: 🚨BREAKING. From a program officer at the National Science Foundation, a list of keywords that can cause a grant to be pulle…
0
7K
0
@BingfeiY
Bingfei Yu
19 days
RT @fadeladib: One of the most important skills I teach my students&postdocs is how to communicate their research. Last week at NSF, I gave…
0
132
0
@BingfeiY
Bingfei Yu
4 months
1
0
1
@BingfeiY
Bingfei Yu
5 months
@PGTimmune Super cool work! A game changer to the field @PGTimmune Have u tried combining this with plate-based peptide stimulation/antigen-specific expansion to decode antigen-TCR specificity?
1
0
4
@BingfeiY
Bingfei Yu
5 months
@iskander Totally agree that we should cover more MHCs beyond A2. But for TCR bispecifics, the TCR affinity needs to be evolved to very high to ensure binding to low surface tumor pMHC. This will lead to cross reactivity especially for CTAs.
1
0
2
@BingfeiY
Bingfei Yu
6 months
RT @DelgoffeLab: Out today in @jitcancer is an exciting an eye-opening project led by Kristin DePeaux, PhD, former student in the lab! In i…
0
7
0
@BingfeiY
Bingfei Yu
7 months
RT @CellReproLab: 🌟1/7 Check out our new pre-print “A cancer #immunotherapy modality based on dendritic cell #reprogramming in vivo”, where…
0
18
0
@BingfeiY
Bingfei Yu
8 months
RT @aimbe: A new congressional blueprint for restructuring the NIH has been released. It proposes consolidating NIH's 27 IC's and centers i…
0
54
0
@BingfeiY
Bingfei Yu
8 months
@SaulPriceman @NatureMedicine @TDorffOnc @StephenForman @pkuhn1 @lpachter @PCFnews Big congrats @SaulPriceman! Fascinating work and can’t wait to read it!
0
0
2
@BingfeiY
Bingfei Yu
8 months
RT @ProfTomEllis: New preprint from our lab is now up on BioRxiv. This time it's a short but sweet one - a very useful method called POLAR-…
0
30
0
@BingfeiY
Bingfei Yu
9 months
@kinglhung @HowardYChang Big congrats King! 🍾🎈🎉
0
0
1
@BingfeiY
Bingfei Yu
9 months
@PeteMullen @StevePilley @LyssiotisLab @BKennedy_aging Congrats Pete and Steve! Beautiful work! Looking forward to next phase of aging immunometabolism:)
1
0
3
@BingfeiY
Bingfei Yu
10 months
RT @RezwanSidd: So excited to finally share this project! We've discovered #seekRNA -a new #RNA that can be reprogrammed to take any cargo…
0
54
0
@BingfeiY
Bingfei Yu
10 months
RT @jptosar: 📌Preprint alert! Can naked extracellular RNA enter cells? Can it escape from endosomes into the cytosol? Can naked extracellu…
0
30
0
@BingfeiY
Bingfei Yu
10 months
RT @thisismadani: Can AI rewrite our human genome? ⌨️🧬 Today, we announce the successful editing of DNA in human cells with gene editors f…
0
961
0
@BingfeiY
Bingfei Yu
10 months
0
0
0
@BingfeiY
Bingfei Yu
10 months
@EvanWeberPhD @Nature @alexdoan96 @kpmueller1 @andy_yhchen Amazing work! Congrats Evan and the team!
1
0
1
@BingfeiY
Bingfei Yu
10 months
RT @NatureRevCancer: NEW content online! Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications
0
92
0
@BingfeiY
Bingfei Yu
10 months
RT @AdamCribbs: Latest #BioRxiv on scRNA-seq reveals critical issues with droplet-based beads: Truncation compromises UMI identification, l…
0
42
0
@BingfeiY
Bingfei Yu
11 months
@CalebLareau @tsion_abay @MerilTakizawa @ChaligneRonan @Satpathology Congrats @CalebLareau! Beautiful work! Is it possible to sort/profile SNV+ population?
1
0
1